Patient | Gender | Age | Smoking | Disease history | CT diagnosis* | Sample | Sputum stain* | Xpert* |
---|---|---|---|---|---|---|---|---|
1 | M | 48 | N | N | U/U, M | BALF | Neg × 3 | L |
2 | M | 80 | 1200 | Pulmonary emphysema | U/U, M | BALF | Neg × 3 | L |
3 | M | 35 | N | Uremia, Post renal transplant | U, L/U, M, L | BALF | Neg × 2 | L |
4 | M | 29 | N | N | U/ (−) | BALF | Neg × 2 | M |
5 | M | 62 | N | T2DM | U/U | BALF | Neg × 4 | L |
6 | F | 19 | N | N | L/ (−) | BALF | Neg × 3 | L |
7 | M | 68 | N | N | U/U, M | BALF | Neg × 3 | Neg |
8 | M | 68 | 1000 | Hypertension, LA, Syphilis | L/ (−) | BALF | 1 +  | H |
9 | F | 77 | N | Hypertension | U, L/U, M, L | BALF | Neg × 3 | L |
10 | F | 56 | N | Hepatitis B | (−)/U, M | BALF | Neg × 2 | L |
11 | F | 78 | N | COPD, Bronchiectasis, CI | L/M, L | BALF | Neg × 3 | M |
12 | F | 78 | N | N | L/ (−) | BALF | Neg × 2 | L |
13 | F | 45 | N | Heart failure, PAH | U/U, M, L | BALF | Neg × 3 | M |
14 | F | 30 | N | AML, UCBCT | U, L/U, M, L | BALF | Neg × 3 | L |
15 | M | 57 | N | LUSC of left lung | U/ (−) | BALF | Neg × 2 | L |
16 | M | 57 | 800 | N | U, L/U, M, L | BALF | Neg × 2 | M |
17 | M | 38 | N | N | (−)/U, M | BALF | Neg × 2 | L |
18 | F | 24 | N | N | U, L/ (−) | BALF | Neg × 3 | H |
19 | M | 62 | N | N | (−)/U, M | BALF | Neg × 3 | H |
20 | M | 35 | N | N | (−)/U, M, L | BALF | Neg × 2 | L |
21 | M | 81 | 800 | COPD, CHD | (−)/M, L | BALF | Neg × 3 | L |
22 | F | 78 | N | N | U/ (−) | R-EBUS-TBLB | Neg × 2 | H |
23 | M | 38 | N | N | U, L/ (−) | R-EBUS-TBLB | Neg × 2 | L |
24 | M | 80 | 2400 | N | U/U | R-EBUS-TBLB | Neg × 2 | M |
25 | F | 79 | N | N | (−)/M, L | R-EBUS-TBLB | Neg × 2 | L |
26 | M | 56 | N | CHD | U/ (−) | R-EBUS-TBLB | Neg × 3 | Neg |
27 | M | 21 | N | N | (−)/L | R-EBUS-TBLB | Neg × 2 | M |
28 | F | 65 | N | N | U, L/U, M, L | CPLP | Neg × 2 | L |
29 | M | 32 | 30 | N | (−)/U | CPLP | Neg × 2 | M |
30 | M | 25 | 100 | N | U/ (−) | CPLP | Neg × 2 | L |
31 | M | 84 | 600 | T2DM, Hypertension | (−)/U | CPLP | Neg × 2 | L |
32 | M | 56 | N | Esophagus cancer | U/ (−) | CPLP | Neg × 2 | L |
33 | M | 55 | 600 | T2DM | (−)/U | CPLP | Neg × 2 | H |
34 | M | 41 | N | Epilepsy | U, L/U, M, L | CPLP | Neg × 3 | L |
35 | F | 16 | N | Nephrotic syndrome | (−)/L | CPLP | Neg × 2 | L |
36 | F | 67 | N | N | L/L | CPLP | Neg × 2 | L |